.png){kind=icon}
OECD 455: Estrogen receptor transcriptional activation (ERTA)
Estrogen Receptor (ER) Transcriptional Activation Testing (OECD 455/OPPTS 890.1300) is used for Level 2 testing of substances with potential to be endocrine disruptors. It evaluates the substance’s estrogen agonist activity mediated by human ER-alpha (hERα) in a human cell line modified to incorporate a firefly luciferase gene (HeLa-9903). If a substance binds to hERα, it enters the nucleus and transactivates the luciferase gene. Increased transcriptional activity of the gene is determined by lysing the cells and running an assay which measures bioluminescence produced by the action of luciferase on its substrate, luciferin. Concentration–response relationships are reported, with RPCMax, PCMax, PC50 and/or PC10 and EC50 values.
-
OECD 442C: Direct peptide reactivity assay (DPRA) for skin sensitization
Genetic, Acute, In Vitro Alternate -
Eye irritation
Genetic, In Vitro Alternate, Acute -
OECD 432: In vitro phototoxicity (Balb/c 3T3)
Toxicology, In Vitro Alternate -
OECD 439: In vitro skin irritation (EpiSkin™ / EpiDerm™)
Toxicology, In Vitro Alternate -
OECD 493: Human recombinant estrogen receptor (hrER)
In Vitro Alternate
